PREDILIFE

- EUR (-)

- 15 min delayed data - Euronext Paris

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	ALPRE
ISIN:	FR0010169920

PREDILIFE overview

> Analyses

Londinia AI has published a new analysis for pierrott.

0
74002
15120
0

PREDILIFE - Daily

Timeframe : Daily - Simple chart
Status : IN PROGRESS...

PREDILIFE is part of a very strong bullish trend. Traders may consider trading only long positions (at the time of purchase) as long as the price remains well above . The next resistance located at…

Thank you Reply Chart

> Analyses

Londinia AI has published a new analysis for pierrott.

0
74002
15120
0

PREDILIFE - Weekly

Timeframe : Weekly - Simple chart
Status : WITHOUT TARGET

PREDILIFE is part of a very strong bullish trend. Traders may consider trading only long positions (at the time of purchase) as long as the price remains well above 9.20 EUR.

Thank you Reply Chart

> News Actusnews published a news.

IN EXTENSO FINANCE UPDATES COVERAGE ON PREDILIFE STOCK; TARGET PRICE OF EUR 25.07 REPRESENTS +391% POTENTIAL UPSIDE • • Actusnews • Stocks • More PREDILIFE news...

PRESS RELEASE MAY 1 st , 2024 . IN EXTENSO FINANCE UPDATES COVERAGE ON PREDILIFE STOCK; TARGET PRICE OF €25.07 REPRESENTS +391% POTENTIAL UPSIDE Villejuif, France, May 1 st , 2024, 08:30 AM CET – PREDILIFE (Euronext Growth : ALPRE FR0010169920), a specialist in artificial intelligence methods for predicting the risk of pathologies for personalized medicine, announces the update of its target price by In Extenso Finance, an investment bank dedicated to small and medium-sized companies in...

Thank you Chart

> News Actusnews published a news.

Valuation of MammoRisk(R) software • • Actusnews • Stocks • More PREDILIFE news...

PRESS RELEASE APRIL 25, 2024 . Valuation of MammoRisk ® software Villejuif, France (April 25, 2024) – PREDILIFE (Euronext Growth: ALPRE FR0010169920), a specialist in artificial intelligence methods for predicting the risk of pathologies for personalized medicine, announces the value of its MammoRisk ® software following an analysis by SORGEM Evaluation. PREDILIFE wanted to value the MammoRisk ® software to examine the possibility of licensing it to industrial partners and mandated SORGEM...

Thank you Chart

Load more content